Skip to main content
Fig. 4 | BMC Infectious Diseases

Fig. 4

From: Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile

Fig. 4

Preferred sensitivity and acceptable trade-offs between sensitivity and price. Over 50% of respondents see current price of HBV DNA, HCV RNA, and to a lesser extent HCV cAg, is seen as a major barrier to scale up the testing a. Half of respondents consider that 95% as an acceptable diagnostic sensitivity for a one-step diagnostic test whereas 43% prefer 98% b. Respondents were willing to pay more for a higher sensitivity and were willing to compromise on sensitivity for a cheap test c and d

Back to article page